In a post-hoc analysis of 89bio's ENLIVEN phase 2b trial of pegozafermin presented at The Liver Meeting, data suggested that the therapy reduced progression to cirrhosis for MASH patients

CEO Rohan Palekar describes this result that was presented at the meeting, as well as other biomarker findings. Plus, he highlights three phase 3 trials the company currently has ongoing, including one that will read out next year.